Cumberland Pharmaceuticals Inc.
CPIX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $38 | $40 | $42 | $36 |
| % Growth | -4.3% | -5.9% | 16.7% | – |
| Cost of Goods Sold | $7 | $6 | $9 | $9 |
| Gross Profit | $31 | $33 | $33 | $27 |
| % Margin | 82.6% | 84.7% | 78.3% | 75.5% |
| R&D Expenses | $5 | $6 | $7 | $6 |
| G&A Expenses | $11 | $11 | $10 | $10 |
| SG&A Expenses | $28 | $29 | $27 | $25 |
| Sales & Mktg Exp. | $17 | $18 | $17 | $15 |
| Other Operating Expenses | $5 | $8 | $5 | $4 |
| Operating Expenses | $38 | $43 | $39 | $35 |
| Operating Income | -$6 | -$10 | -$6 | -$8 |
| % Margin | -17% | -24.2% | -13.6% | -21.3% |
| Other Income/Exp. Net | -$0 | $3 | $0 | $2 |
| Pre-Tax Income | -$6 | -$6 | -$6 | -$6 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$6 | -$6 | -$6 | -$4 |
| % Margin | -17.1% | -15.9% | -13.3% | -9.7% |
| EPS | -0.46 | -0.44 | -0.38 | -0.24 |
| % Growth | -4.5% | -15.8% | -58.3% | – |
| EPS Diluted | -0.46 | -0.44 | -0.38 | -0.24 |
| Weighted Avg Shares Out | 14 | 14 | 15 | 15 |
| Weighted Avg Shares Out Dil | 14 | 14 | 15 | 15 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $0 |
| Depreciation & Amortization | $6 | $8 | $5 | $5 |
| EBITDA | $0 | $2 | $0 | -$1 |
| % Margin | 0.5% | 6.3% | 0.8% | -2.4% |